Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has developed the IRAE (Inhibition Removal and Activation Enhancement) bifunctional antibody platform to enhance the therapeutic effect compromised by suppression and insufficient activation of immune cells during immunotherapy.
The IRAE bifunctional antibody platform concurrently blocks/activates the biological functions mediated by two antigens/epitopes, unlocking potential biological effects beyond the reach of single target antibodies.
The pipeline developed based on the IRAE bifunctional antibody platform exhibits superior druggability and industrial efficiency, effectively addressing limitations on molecule druggability as well as many other CMC challenges caused by poor stability, low expression level, and structural mismatch of bispecific antibodies.
TPEBEN（Tumor Penetration Enhancement By Engineered Nanobody）is a globally leading nano dual antibody ADC platform independently developed by Novatim.
Based on the core logic of TPEBEN technology and differentiated innovative design, Novatim taps into three major modules: VHHdesign, KYtoxin, KYDARall.
VHHdesign enables the screening of nanobodies with high endocytosis, along with enhanced druggability engineering due to modification of antibodies, and better pharmacokinetics as a result of optimized molecular surface properties.
KYtoxin an independently developed toxin platform with proprietary intellectual property by Novatim, specializes in two toxin directions: topoisomerase inhibitors and microtubule protein inhibitors. Developed from scratch, KYtoxin toxin exhibits superior water solubility and a stronger bystander effect.
KYDARall has elevated the production purity of ADC to unprecedented heights. Through innovative antibody structure design, the company has achieved significant breakthroughs in DAR2, DAR4, and DAR6, with product purity consistently exceeding 95%. Notably, the purity of DAR4 product has reached around 98%, leading the DAR4 industry.
K2 CAR-T, an enhanced dual target CAR-T independently developed by Novatim, effectively addresses the limitations posed by traditional CAR-T therapy for hematological malignancies, known for their recurrence propensity and lack of efficacy against solid tumors.
CAR-T cells’ limited migration to tumor cells and CAR-T’s restrained expansion are key factors hindering efficacy. K2 CAR-T overcomes these challenges through three technological innovations:
Optimization of antibody surface properties modulates the memory phenotype differentiation of CAR-T cells, enhancing their efficient infiltration into tumors.
The modification of CAR structure regulates the cluster morphology of antigen reaction between CAR-T cells and tumor cells, sustaining efficient tumor killing while minimizing depletion.
Enhanced structures are designed for intracellular signaling domains to promote CAR-T expansion within the tumor’s microenvironment.
Leveraging the K2 CAR-T technology, Novatim has independently developed four enhanced dual target CAR-T pipelines：KQ-2003（BCMA & CD19）、KQ-2002（CD19 & CD22）、KQ-2206（CD70 dual epitope）、RD27 （BCMA & GPRC5D）
